Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dWBeCfbwoceOogxZrHPq

October 17, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
 
  • Venture investors stand to gain from biotech IPOs
    Many venture capital firms have exited the biotechnology market, but those that remain stand to gain from recent initial public offerings, Luke Timmerman writes. The IPO market is approaching a balanced state -- not so hot investors get burned and not so cold no one starts or invests in new companies -- giving VCs a chance to make money and small biotech firms some leverage with potential buyers, Timmerman writes. Xconomy (10/15) LinkedInFacebookTwitterEmail this Story

With in-depth industry knowledge, GE Capital, Healthcare Financial Services' dedicated Life Science Finance team has worked with more than 500 companies and provided over $2.5 billion in financing to the market. Stop just banking. And start building. Click here to find out more.
  Health Care & Policy 
  • Lilly's ramucirumab prolongs survival in gastric cancer trial
    Eli Lilly's experimental drug ramucirumab met the main endpoint of improved overall survival and the secondary goal of extended progression-free survival in patients with metastatic gastric cancer in a late-stage trial. Lilly said the findings boosts its confidence in ramucirumab, which is in six late-stage trials for breast, gastric, colorectal, lung and hepatocellular cancers. PharmaTimes (U.K.) (10/16) LinkedInFacebookTwitterEmail this Story
  • Boys with Pelizaeus-Merzbacher disease treated with stem cells
    Researchers from the University of California, San Francisco, have succeeded in transplanting neural stem cells into four boys with Pelizaeus-Merzbacher disease. Imaging tests showed the stem cells allowed for an increase in myelin, the brain cell insulator that is eaten away by the disease, according to the study published in Science Translational Medicine. Researchers said that since there was no control group, larger studies must be performed. Los Angeles Times/Science Now blog (tiered subscription model) (10/12) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Celgene will fund drug discovery startup
    Celgene will provide seed and venture funding to PharmAria for research on cancer and fibrotic disease drugs and will work with the startup to secure additional venture capital in return for an equity stake and licensing options. "The unique deal structure with Celgene provides PharmAria with the ability to create significant value for investors, while simultaneously providing Celgene with access to additional world class research and novel clinical candidates for its pipeline," said PharmAria president John Hutchison. Genetic Engineering & Biotechnology News (10/15) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  • Prop 37 campaigns clash in California
    Biotech seed makers, farmers, food companies and grocers are campaigning against California's Proposition 37 biotech food labeling ballot measure. "The label would be the equivalent of a 'skull and crossbones' when the FDA has ruled along with all the scientific studies that there is no substantial difference between biotech ingredients and other counterparts," said Kathy Fairbanks of the "No on 37" campaign. U.S. News & World Report (10/16) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Algae-based fuels are still years away from the market
    Sapphire Energy, Synthetic Genomics, Phycal and Aurora Algae are among the companies worldwide vying to produce commercial quantities of fuel from algae. "This technology is so compelling -- and it will make such a big difference -- that, once it gets out of the gate, it will ramp up very quickly," said Sapphire Energy CEO Cynthia Warner. However, even some supporters acknowledge that algae-based fuels might not reach the market for at least another five to 10 years, with high capital and operating costs seen as the major hindrance to commercialization. The Guardian (London) (10/15) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
In times of change, learners inherit the earth; while the learned find themselves beautifully equipped to deal with a world that no longer exists."
--Eric Hoffer,
American social writer


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information